Literature DB >> 908870

Specific determination of quinidine and (3S)-3-hydroxyquinidine in human serum by high-pressure liquid chromatography.

D E Drayer, K Restivo, M M Reidenberg.   

Abstract

A sensitive and selective HPLC assay was developed to measure quinidine and (3S)-3-hydroxyquinidine in the serum of patients receiving quinidine. The method involves analysis of a benzene extract of alkalinized serum by a high-pressure liquid chromatograph containing a reverse phase column and a fluorescence detector. The lower limit of sensitivity of this method for these compounds is 5 ng/ml. The coefficients of variation of the assay for quinidine and (3S)-3-hydroxyquinidine are 2% and 6%, respectively. Samples of serum from 10 cardiac patients were found to contain (3S)-3-hydroxyquinidine and quinidine in ratios ranging from 0.18 to 1.0 (mean, 0.38 +/- 0.28 [S.D.]). Quinidine serum levels in these patients determined by HPLC averaged 80% of those determined on the same samples by the routinely used fluorometric assay. The reason for the discrepancy is that this latter assay, involving a double extraction with quantitation in sulfuric acid by fluorometry, is nonspecific for quinidine. The (3S)-3-hydroxy metabolite, having a fluorescence intensity similar to that of quinidine, is 60% extracted under the fluorometric assay conditions.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 908870

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  11 in total

1.  Lack of effect of treatment with human recombinant-tumour necrosis factor (HrTNF) on the binding of quinidine to alpha 1-acid glycoprotein (AGP).

Authors:  J A Barnett; D E Brenner; P J Creaven; D Lalka
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

Review 2.  Pharmacologically active metabolites of drugs and other foreign compounds. Clinical, pharmacological, therapeutic and toxicological considerations.

Authors:  D E Drayer
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

3.  The second peak in the serum levels curve after oral administration of a slow-release quinidine dosage form: effect of food.

Authors:  J Spénard; G Sirois; M A Gagnon
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

4.  Antiarrhythmic drugs: clinical pharmacology and therapeutic uses.

Authors:  J L Anderson; D C Harrison; P J Meffin; R A Winkle
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

5.  Divergence in pharmacokinetic parameters of quinidine obtained by specific and nonspecific assay methods.

Authors:  T W Guentert; R A Upton; N H Holford; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1979-06

6.  Comparative bioavailability study of three sustained release quinidine formulations.

Authors:  W A Mahon; J S Leeder; M M Brill-Edwards; J Correia; S M MacLeod
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

7.  Urinary excretion kinetics of intact quinidine and 3-OH-quinidine after oral administration of a single oral dose of quinidine gluconate in the fasting and non-fasting state.

Authors:  J M St-Onge; G Sirois; M A Gagnon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983 Oct-Dec       Impact factor: 2.441

8.  A quinine a day keeps the leg cramps away?

Authors:  A Warburton; J P Royston; C J O'Neill; P W Nicholson; R D Jee; M J Denham; S M Dobbs; R J Dobbs
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

10.  Lack of effect of smoking on the metabolism and pharmacokinetics of quinidine in patients.

Authors:  D J Edwards; J E Axelson; J P Visco; S vanEvery; R L Slaughter; D Lalka
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.